Search results | Servier


Partnering Agreements with Servier

This report provides all the information you require to better understand Servier and its partnering interests and activities over the past seven years.



Servier is a top pharmaceutical company based in Suresnes, France

Servier: Investing in and leading research like no other

Servier is a European research based pharmaceutical company focusing on the areas of oncology, cardiovascular and Central Nervous System diseases.

Servier: Partnering activity 2005-2013

Servier is a top independent pharmaceutical company committed to progressing medicine.  The company’s partnering, collaborative R&D and licensing activities are reviewed here

Servier: Company Profile

Servier, a top pharmaceutical company, is reviewed in terms of partnering and licensing interests and activity over recent years

Servier, a big pharma company in partnership with NovAliX for drug discovery research program

Servier, a big pharma company has inked a collaboration deal with NovAliX for small molecule drug discovery

Servier seals a pharma partners pact with Ethical Oncology Science

Ethical Oncology Science and Servier, a big pharma company have sealed a pharma partners collaboration and license agreement to further develop EOS’ antitumor drug E-3810.

miRagen and Servier in cardiovascular tie up could be worth $1 billion

The collaboration focuses on developing microRNA-based therapeutics for cardiovascular and muscle disease

Xoma and Servier sign licensing agreement for anti-inflammatory compounds

Xoma has signed a licensing, development and option agreement with Servier, France’s largest privately owned pharmaceutical company, for XOMA 052.

Current Agreements Deal Analysis Update : December 2014

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in November 2014 and give you an exclusive opportunity to gain discounted annual subscription access to our database.

Pharmacyclics: Partnering activity 2009-2014

Pharmacyclics, listed as a new big biotech entrant in 2014, works to improve the lives of cancer affected patients by entering into strategic partnering deals to support its product pipeline.


Sorry, your search returned no results.


Servier and GeNeuro in GNbAC1 multiple sclerosis deal

GeNeuro has entered into a strategic partnership with Servier to develop and market GNbAC1 in Multiple Sclerosis

Servier gains ITCA 650 for Type 2 diabetes

Intarcia Therapeutics announced the successful start of a strategic partnership with Servier outside the United States and Japan, to develop and commercialize ITCA 650

Cellectis joins in a pharma partnering with Servier

Cellectis has signed a pharma partnering collaboration agreement with Servier to develop and commercialize novel product candidates targeting leukemia and solid tumors for $150 million.

Xention and Servier pharma partners for XEN-D0103

XENTION and SERVIER pharma partners by entering into a multi-year agreement for the development and commercialisation of XEN-D0103, a selective Kv1.5 modulator discovered and developed by Xention for the treatment of atrial fibrillation

M&A news: Servier agrees to buy shares in Egis

French big pharma giant Servier has offered to buy the shares in Hungarian pharmaceuticals maker Egis creating M&A news

Shanghai Institute pharma partners with Servier for lucitanib

The Shanghai Institute of Materia Medica pharma partners with Servier, a big pharma company, on China development of lucitanib, a clinical-stage anti-angiogenic cancer drug

Pharma partners MacroGenics trigger first milestone payment from Servier

Pharma partners, MacroGenics, announced that the first patient has been dosed in a Phase 1 dose expansion cohort trial of MGA271.

Amgen and Servier terminate cardiovascular pharma deals

Amgen and Servier have terminated pharma deals involving the cardiovascular drug Procoralan.

Amgen pharma deals Servier for cardiovascular drugs licensing

Amgen and Servier announced new pharma deals leveraging each company’s commitment to cardiovascular disease.

Servier, a big pharma company in partnership with NovAliX for drug discovery research program

Servier, a big pharma company has inked a collaboration deal with NovAliX for small molecule drug discovery